Subscribe To

Price Alert Latest News Economic Calendar News

BLCO / Bausch + Lomb IPO: What You Need to Know

Bausch + Lomb, a well-known leader in eye care, is about to hit Wall Street in what investment bankers almost certainly hope will jump-start a weak initial public offering (IPO) market. Bausch Health Companies (BHC) is a global healthcare stock that develops pharmaceuticals, medical devices and over-the-counter medications, with focus areas in eye health, gastroenterology and dermatology. Read More

Demo Live Account See Partner Details

Content Topics

Bausch

Lomb

Ipo

What

Need

Know

Stock

BLCO

Posted: May 3 2022, 12:10

Author Name: Kiplinger

BLCO News

By Seeking Alpha
November 1, 2023

Bausch + Lomb Corporation (BLCO) Q3 2023 Earnings Call Transcript

Bausch + Lomb Corporation (NYSE:BLCO ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants George Gadkowski - Vice Presi

By Zacks Investment Research
September 19, 2023

Is the Options Market Predicting a Spike in Bausch + Lomb (BLCO) Stock?

Investors need to pay close attention to Bausch + Lomb (BLCO) stock based on the movements in the options market lately.

By Zacks Investment Research
August 2, 2023

Bausch + Lomb (BLCO) Beats Q2 Earnings and Revenue Estimates

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to ea

By Zacks Investment Research
July 6, 2023

BLCO or DOCS: Which Is the Better Value Stock Right Now?

Investors interested in Medical Services stocks are likely familiar with Bausch + Lomb (BLCO) and Doximity (DOCS). But which of these two stocks is mo

By Zacks Investment Research
May 3, 2023

Bausch + Lomb (BLCO) Q1 Earnings Lag Estimates

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.10 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to ea

By Seeking Alpha
February 27, 2023

Bausch + Lomb: Brent Saunders Return Bodes Well For Shareholders

Brent Saunders led Bausch + Lomb Corporation when it was sold to Valeant Pharmaceuticals. He later led and sold competitor Allergan to AbbVie.

By Seeking Alpha
February 22, 2023

Bausch + Lomb Corporation (BLCO) Q4 2022 Earnings Call Transcript

Bausch + Lomb Corporation (NYSE:BLCO ) Q4 2022 Earnings Conference Call February 22, 2023 8:00 AM ET Company Participants Art Shannon – Investor Rel

By Market Watch
February 22, 2023

Bausch + Lomb beats Q4 profit and revenue estimates

Bausch + Lomb Corp. BLCO, -2.01% said Wednesday it had a loss of $1 million, or breakeven on a per-share basis, for the fourth quarter, after earnings

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.